# Avelumab in G3 NEC

> **NCT03278405** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 10 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03278405
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2019-08-09
- **Final completion:** 2020-03-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278405, "Avelumab in G3 NEC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03278405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*